Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From May 2019 to May 2024
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging such as Type 2 Diabetes, announced that it will
be presenting at the American Diabetes Association’s
68th Annual Scientific Sessions in San
Francisco.
Peter Elliott, PhD, Senior Vice President of Development at Sirtris,
will speak at the symposium titled Speed and Endurance, Nature or
Nurture? His talk is on Sunday, June 8 beginning at 3:30 pm.
Sirtris will also give two poster presentations: Activation of the
Protein Deacetylase SIRT1 Blunts Pro-Inflammatory Pathways in vivo;
and Novel Small Molecule Activators of SIRT1 as a Therapeutic
Approach to Type 2 Diabetes: The Identification of SRT100 as a Clinical
Candidate. Both poster presentations will be on Sunday, June 8
beginning at noon.
Sirtris has announced positive Phase 1b clinical trial results with drug
candidate SRT501, a proprietary formulation of resveratrol, in patients
with Type 2 Diabetes. Sirtris has also developed new chemical entities
(NCEs) that are chemically distinct from and more potent, in vitro, than
resveratrol. The NCEs have been shown to lower glucose and improve
insulin sensitivity in pre-clinical models of Type 2 Diabetes. These
SIRT1 activators have the potential to be a frontline therapy for Type 2
Diabetes.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that the
Company believes control the aging process. Sirtris Pharmaceuticals is
engaged in human clinical trials for Type 2 Diabetes, and is planning
similar trials in cancer, another age-related disease. Sirtris is also
engaged in a human clinical trial for MELAS, a mitochondrial disorder.
The company’s headquarters are in Cambridge,
Massachusetts. On June 2, 2008, GlaxoSmithKline plc announced the
successful completion by an indirect wholly-owned subsidiary of a tender
offer to purchase all of the outstanding shares of Sirtris common stock.
Approximately 97% of Sirtris's outstanding shares were tendered in the
offer.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, the potential therapeutic
effects of SIRT1 activators including NCEs for diseases of aging, such
as Type 2 Diabetes; the success of SIRT1 activators as therapies for
diseases, such as Type 2 Diabetes; the progress and results of
preclinical and clinical studies of SIRT1 activators, such as SRT501 and
Sirtris’ NCEs; and the potential of sirtuin
modulators to receive regulatory approval. These forward-looking
statements about future expectations, plans and prospects of Sirtris
Pharmaceuticals involve significant risks, uncertainties and
assumptions, including risks related to the lack of results that would
provide a basis for predicting whether any of the Company’s
product candidates will be safe or effective, or receive regulatory
approval, the possibility that results of pre-clinical studies are not
necessarily predictive of clinical trial results, the Company’s
potential inability to initiate and complete pre-clinical studies and
clinical trials for its product candidates, the fact that none of the
Company’s product candidates has received
regulatory approvals, the potential inability of the Company to gain
market acceptance of the Company’s product
candidates, and those other risks factors that can be found in the
Company’s filings with the Securities and
Exchange Commission. Actual results may differ materially from those
Sirtris Pharmaceuticals contemplated by these forward-looking
statements. Sirtris Pharmaceuticals does not undertake to update any of
these forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.